Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Feb 27;69(1):3.
doi: 10.1007/s00005-021-00604-x.

Cancer Immunoprevention: Current Status and Future Directions

Mahsa Keshavarz-Fathi  1   2   3 , Nima Rezaei  4   5   6
Affiliations
Review

Cancer Immunoprevention: Current Status and Future Directions

Mahsa Keshavarz-Fathi et al. Arch Immunol Ther Exp (Warsz). .

Abstract

Cancer is one of the most serious diseases affecting health and the second leading cause of death worldwide. Despite the development of various therapeutic modalities to deal with cancer, limited improvement in overall survival of patients has been yielded. Since there is no certain cure for cancer, detection of premalignant lesions, and prevention of their progression are vital to the decline of high morbidity and mortality of cancer. Among approaches to cancer prevention, immunoprevention has gained further attention in recent years. Deep understanding of the tumor/immune system interplay and successful prevention of virally-induced malignancies by vaccines have paved the way toward broadening cancer immunoprevention application. The identification of tumor antigens in premalignant lesions was the turning point in cancer immunoprevention that led to designing preventive vaccines for various malignancies including multiple myeloma, colorectal, and breast cancer. In addition to vaccines, immune checkpoint inhibitors are also being tested for the prevention of oral squamous cell carcinoma (SCC), and imiquimod which is an established drug for the prevention of skin SCC, is a non-specific immunomodulator. Herein, to provide a bench-to-bedside understanding of cancer immunoprevention, we will review the role of the immune system in suppression and promotion of tumors, immunoprevention of virally-induced cancers, identification of tumor antigens in premalignant lesions, and clinical advances of cancer immunoprevention.

Keywords: Actinic keratosis; Biomarker; Colon polyp; Ductal carcinoma in situ of the breast; Immune checkpoint blockade; Immunosurveillance; Oral proliferative verrucous leukoplakia; Precancerous lesion; Precursor; Prevention; Preventive vaccine; Prophylactic vaccine; Smoldering myeloma; Tumor antigen.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Aaltonen LA, Peltomäki P, Mecklin JP et al (1994) Replication errors in benign and malignant tumors from hereditary nonpolyposis colorectal cancer patients. Cancer Res 54:1645–1648 - PubMed
    1. Adams S, Greeder L, Reich E et al (2011) Expression of cancer testis antigens in human BRCA-associated breast cancers: potential targets for immunoprevention? Cancer Immunol Immunother 60:999–1007 - PubMed
    1. Al-Khayal K, Abdulla M, Al-Obaid O et al (2016) Differential expression of mucins in Middle Eastern patients with colorectal cancer. Oncol Lett 12:393–400 - PubMed
    1. Amanti C, Midiri G, Benedetti M et al (1985) Tissue CEA detection by immunoperoxidase (PAP) test in colorectal polyps: correlations with the degree of dysplasia. J Surg Oncol 28:222–226 - PubMed
    1. Atanackovic D, Hildebrandt Y, Jadczak A et al (2010) Cancer-testis antigens MAGE-C1/CT7 and MAGE-A3 promote the survival of multiple myeloma cells. Haematologica 95:785–793 - PubMed

MeSH terms

LinkOut - more resources